StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-19 | $0.07 | $0.07 | -2.85% | 0.4M |
| 05-20 | $0.07 | $0.07 | +2.11% | 0.1M |
| 05-21 | $0.07 | $0.07 | +0.61% | 0.1M |
| 05-22 | $0.07 | $0.07 | -0.76% | 0.1M |
| 05-26 | $0.07 | $0.07 | +0.00% | 0.1M |
Next report date, year-over-year trend, and recent quarter history.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows PVCT's percentile within the scored universe — observational ranking, not a recommendation.
No sell-side coverage available for PVCT yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $336.11K | $336.11K | $336.11K | $278.63K |
Operating Income | $-5.29M | $-4.17M | $-2.90M | $-1.10M |
Net Income | $-5.43M | $-4.27M | $-2.95M | $-1.14M |
EPS (Diluted) | $-0.01 | $-0.01 | $-0.01 | $0.00 |
Total Assets | $697.50K | $419.90K | $722.38K | $666.26K |
Total Liabilities | $7.00M | $6.59M | $6.60M | $5.74M |
Cash & Equivalents | $251.29K | $72.48K | $385.93K | $390.44K |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 420.28M | 420.28M | 420.28M | 420.28M |
PROVECTUS BIOPHARMS